Parallax Volatility Advisers
ZYNE

Parallax Volatility Advisers’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Parallax Volatility Advisers’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,722
Closed -$22K – 4645
2017
Q4 		$22K Buy
+1,722
New +$19.7K ﹤0.01% 3647

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallax Volatility Advisers's ZYNE Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2018, closing a stake of 1,722 shares — an estimated $22K sold.

Parallax Volatility Advisers first reported a position in ZYNE in Q4 2017 and held it in 1 quarter. The position peaked at $22K in Q4 2017. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,722 Zynerba Pharmaceuticals, Inc shares in Q1 2018, an estimated $22K.
  • Parallax Volatility Advisers first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Zynerba Pharmaceuticals, Inc position peaked at $22K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.